Drug Profile


Alternative Names: Acetylcysteine/mesalamine; Acetylcysteine/mesalazine; ALTH12; Mesalamine/N-acetylcysteine; N-acetylcysteine/mesalamine; N-acetylcysteine/mesalazine; Zoenasa

Latest Information Update: 03 Feb 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Altheus Therapeutics
  • Class Aminosalicylic acids; Anti-inflammatories; Irritable bowel syndrome therapies; Reducing agents; Small molecules; Sulfur amino acids
  • Mechanism of Action Antioxidants; Free radical inhibitors; Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis
  • New Molecular Entity No

Highest Development Phases

  • No development reported Crohn's disease; Gastrointestinal disorders; Ulcerative colitis; Ulcerative proctitis

Most Recent Events

  • 23 Dec 2014 Phase-III clinical trials in Ulcerative colitis in USA (Rectal)
  • 09 Jan 2014 Altheus Therapeutics completes enrolment in the phase II ZA-201 trial for Ulcerative colitis in the US (NCT01586533,
  • 31 Dec 2013 Preclinical trials in Ulcerative colitis, Crohn's disease and Gastrointestinal disorders (in children) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top